A large survey, coordinated by Inserm Unit 1178, “Mental Health and Public Health,” and the University Division of Fondation Vallée, describes the current situation regarding issues and challenges in adolescence.
The indoor air quality in nursing homes has a serious effect on the lung health of elderly residents, according to the findings of a new study.
The 16th edition of Brain Awareness Week will take place in France and in 62 countries around the world from 16 to 22 March 2015. Throughout this week, members of the public can meet researchers from Inserm to gain a better understanding of the brain and learn about the latest research developments in this area.
The 18th National Ear Care Day will take place throughout France on Thursday 12 March 2015.On this occasion, public institutions and non-profit organisations are taking initiatives to welcome the public and inform both the young and not-so-young on risks to their hearing and how to look after it.
A team led by Afsaneh Gaillard (Inserm Unit 1084, Experimental and Clinical Neurosciences Laboratory, University of Poitiers) has just taken an important step in the area of cell therapy.
A study carried out at NeuroSpin (French Atomic Energy Commission [CEA]/Inserm) has shown that even though sounds continue to penetrate the auditory cortex, sleep disrupts the brain’s ability to anticipate them
To celebrate the 30 years of the Médecine/sciences journal, a colloquium is organised the thursday 12th March by Inserm at the Pasteur Institute
Research studies bringing together Inserm, CNRS and Université de Pierre et Marie Curie researchers from the Brain and Spinal Cord Institute in collaboration with a team from the Yale Cardiovascular Research Center, have demonstrated the importance of factor VEGF-C in the activation of neural stem cells, and hence in the production of new neurons.
Inserm, with the help of its subsidiary Inserm Transfert, continues to rise in the 2014 rankings of French patent applicants issued by the European Patent Office (EPO)
A disease is said to be rare if it affects fewer than 1 in 2,000 people, or, for France, fewer than 30,000 people for a given disease.
Preliminary data from the JIKI clinical trial, which is testing the efficacy of favipiravir in reducing mortality associated with Ebola, provide two important pieces of information: • absence of efficacy in individuals who arrive at treatment centres with a very high level of viral replication and who already have serious visceral involvement, • and encouraging signs of efficacy in individuals arriving at treatment centres with a high or moderate level of viral...
